SAN DIEGO, April 26, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com), announced today that the Company received an Issue Notification from the United States Patent and Trademark Office for U.S. Patent Application No. 12/138,603 entitled “Thiazole Compounds, and Compositions and Methods Using Same.” This soon-to-be issued patent claims certain compositions and methods for inhibiting tumor growth related to PrevOnco™, Apricus Bio’s proprietary Phase III-ready cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (“HCC”), or liver cancer. When issued, the patent will provide patent protection into 2029 and will be the Company’s first granted patent in the United States for PrevOnco™.
